Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.

Delto JC, Kobayashi T, Benson M, McKiernan J, Abate-Shen C.

Oncotarget. 2013 Feb;4(2):269-76.

2.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

3.

The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.

Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F.

J Urol. 2013 Sep;190(3):857-62. doi: 10.1016/j.juro.2013.03.097. Epub 2013 Mar 29.

PMID:
23545101
4.

Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.

Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, Abate-Shen C.

Cancer Prev Res (Phila). 2009 Dec;2(12):1008-14. doi: 10.1158/1940-6207.CAPR-09-0169. Epub 2009 Dec 1.

5.

Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.

Velaer KN, Steinberg RL, Thomas LJ, O'Donnell MA, Nepple KG.

Curr Urol Rep. 2016 May;17(5):38. doi: 10.1007/s11934-016-0594-2. Review.

PMID:
26968418
6.

Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.

Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW.

J Urol. 2013 Nov;190(5):1686-91. doi: 10.1016/j.juro.2013.04.120. Epub 2013 May 7.

PMID:
23665400
7.

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.

Cockerill PA, Knoedler JJ, Frank I, Tarrell R, Karnes RJ.

BJU Int. 2016 Mar;117(3):456-62. doi: 10.1111/bju.13088. Epub 2015 May 23.

8.

In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.

Mugabe C, Matsui Y, So AI, Gleave ME, Baker JH, Minchinton AI, Manisali I, Liggins R, Brooks DE, Burt HM.

Clin Cancer Res. 2011 May 1;17(9):2788-98. doi: 10.1158/1078-0432.CCR-10-2981. Epub 2011 Feb 28.

9.

Intravesical therapy for bladder cancer.

Williams SK, Hoenig DM, Ghavamian R, Soloway M.

Expert Opin Pharmacother. 2010 Apr;11(6):947-58. doi: 10.1517/14656561003657145. Review.

PMID:
20205607
10.

Update on intravesical agents for non-muscle-invasive bladder cancer.

Shariat SF, Chade DC, Karakiewicz PI, Scherr DS, Dalbagni G.

Immunotherapy. 2010 May;2(3):381-92. doi: 10.2217/imt.10.1. Review. Erratum in: Immunotherapy. 2014;6(11):1238.

11.

Gemcitabine in bladder cancer.

El Karak F, Flechon A.

Expert Opin Pharmacother. 2007 Dec;8(18):3251-6. Review.

PMID:
18035967
12.

Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.

Horinaga M, Fukuyama R, Iida M, Yanaihara H, Nakahira Y, Nonaka S, Deguchi N, Asakura H.

Urology. 2010 Nov;76(5):1267.e1-6. doi: 10.1016/j.urology.2010.03.028.

PMID:
21056277
13.

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.

Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, Wilson SS, Benson M, Lerner SP, Tangen CM, Thompson IM.

J Urol. 2013 Oct;190(4):1200-4. doi: 10.1016/j.juro.2013.04.031. Epub 2013 Apr 15.

14.
16.

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology.

Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12. Review.

PMID:
23827737
17.

Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.

Yuh BE, Ruel N, Wilson TG, Vogelzang N, Pal SK.

J Urol. 2013 May;189(5):1682-6. doi: 10.1016/j.juro.2012.10.120. Epub 2012 Nov 1. Review.

18.

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

Lamm D, Brausi M, O'Donnell MA, Witjes JA.

Urol Oncol. 2014 Jan;32(1):35.e21-30. doi: 10.1016/j.urolonc.2013.02.010. Epub 2013 Apr 28. Review.

PMID:
23628309
19.

Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance.

Morabito F, Rossi R, Graziano ME, Ferrando U, Lancini V, Cretarola E, Conti G, Luporini AC, Muto G, Castelli E, D'Urso L, Razionale P, Lissoni G, Simone M, Francesca F, Sommariva M, Casu M, Hurle R.

Arch Ital Urol Androl. 2006 Mar;78(1):1-4.

PMID:
16752879
20.

Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.

Chen J, Yao Z, Qiu S, Chen L, Wang Y, Yang J, Li J.

Cardiovasc Intervent Radiol. 2013 Dec;36(6):1521-6. doi: 10.1007/s00270-013-0594-2. Epub 2013 Mar 20.

PMID:
23511989

Supplemental Content

Support Center